---
figid: PMC6590289__HEP-69-376-g007
figtitle: 'Inhibition of Cyclin‐Dependent Kinase 5: A Strategy to Improve Sorafenib
  Response in Hepatocellular Carcinoma Therapy'
organisms:
- NA
pmcid: PMC6590289
filename: HEP-69-376-g007.jpg
figlink: /pmc/articles/PMC6590289/figure/hep30190-fig-0007/
number: F7
caption: Summary. (A) The treatment of HCC cells with sorafenib causes an inhibition
  of VEGFR and its downstream targets RAS and RAF. (B) In turn, this leads to the
  compensatory activation of growth factor receptor signaling, which allows tumor
  cells to maintain proliferation and migration, mediated via the PI3K/AKT pathway.
  After activation, growth factor receptors have to be trafficked via the endosomal
  system and are either degraded via lysosomes or recycled via endosomes. (C) We uncovered
  that Cdk5 inhibition interferes with intracellular trafficking leading to an increase
  in vesicle size and an accumulation of respective cargos. (D) Thereby an inhibition
  of Cdk5 prevents the sorafenib‐induced compensatory activation of growth factor
  receptors and respective downstream targets and enhances the antitumor effects of
  sorafenib.
papertitle: 'Inhibition of Cyclin‐Dependent Kinase 5: A Strategy to Improve Sorafenib
  Response in Hepatocellular Carcinoma Therapy.'
reftext: Maximilian A. Ardelt, et al. Hepatology. 2019 Jan;69(1):376-393.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9543028
figid_alias: PMC6590289__F7
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
redirect_from: /figures/PMC6590289__F7
ndex: b5a5f52f-dec4-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6590289__HEP-69-376-g007.html
  '@type': Dataset
  description: Summary. (A) The treatment of HCC cells with sorafenib causes an inhibition
    of VEGFR and its downstream targets RAS and RAF. (B) In turn, this leads to the
    compensatory activation of growth factor receptor signaling, which allows tumor
    cells to maintain proliferation and migration, mediated via the PI3K/AKT pathway.
    After activation, growth factor receptors have to be trafficked via the endosomal
    system and are either degraded via lysosomes or recycled via endosomes. (C) We
    uncovered that Cdk5 inhibition interferes with intracellular trafficking leading
    to an increase in vesicle size and an accumulation of respective cargos. (D) Thereby
    an inhibition of Cdk5 prevents the sorafenib‐induced compensatory activation of
    growth factor receptors and respective downstream targets and enhances the antitumor
    effects of sorafenib.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Pvr
  - gfr
  - nac
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - ras
  - Ras64B
  - Ras85D
  - lds
  - Raf
  - Pdk1
  - Atg8a
  - Dsor1
  - Mtk
  - Akt
  - Cdk4
  - Cdk5
  - Erk7
  - rl
  - Mtor
  - Tor
  - tor
  - Egfr
  - KDR
  - FLT1
  - FLT4
  - RAPGEF5
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - KRAS
  - HRAS
  - NRAS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - PDK1
  - PDPK1
  - MAP1LC3A
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - AKT1
  - AKT2
  - AKT3
  - CDKL1
  - CDKL2
  - CDKL3
  - CDKL4
  - CDKL5
  - CDK3
  - CDK4
  - CDK5
  - CDK6
  - CDK7
  - CDK8
  - CDK9
  - CDK10
  - CDK11A
  - CDK11B
  - CDK12
  - CDK13
  - CDK14
  - CDK15
  - CDK16
  - CDK17
  - CDK18
  - CDK19
  - CDK20
  - CDK1
  - CDK2
  - EPHB2
  - MAPK1
  - MAPK3
  - MTOR
  - RORC
  - Sorafenib
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
